Increasing proportion of clinical trials using noninferiority end points.

This study was funded in part by grants from the National Institutes of Health (T32 HL094301‐01A1 and T32 HL007604‐27). Dr. Bhatt discloses the following relationships ‐ Advisory Board: Medscape Cardiology; Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers; Chair: American Heart Association Get With The Guidelines Science Subcommittee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees); Research Grants: Amarin, AstraZeneca, Bristol‐Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda. Drs. Murthy and Desai have received consulting fees from Novo Nordisk. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Duke Scholars

Author Amit Navin Vora Medicine, Cardiology